Research and Markets (http://www.researchandmarkets.com/research/xfgrsk/bacterial) has announced the addition of the "Bacterial Conjunctivitis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Bacterial Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Conjunctivitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- List of Tables
- List of Figures
- Introduction
- Bacterial Conjunctivitis Overview
- Therapeutics Development
- Pipeline Products for Bacterial Conjunctivitis - Overview
- Bacterial Conjunctivitis - Therapeutics under Development by Companies
- Bacterial Conjunctivitis - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Bacterial Conjunctivitis - Products under Development by Companies
-
Bacterial Conjunctivitis - Companies Involved in Therapeutics
Development
- Cellceutix Corporation
- China Grand Wuhan General Pharmaceutical Research Institute
- Daiichi Sankyo Company, Limited
- InSite Vision Incorporated
- NovaBay Pharmaceuticals, Inc.
- Ocular Therapeutix, Inc.
- Senju Pharmaceutical Co., Ltd.
- Shire Plc
For more information visit http://www.researchandmarkets.com/research/xfgrsk/bacterial
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106006137/en/